These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38227596)

  • 1. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
    Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
    AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
    Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir based therapy showed CD4
    Gebremedhin T; Aynalem M; Adem M; Geremew D; Aleka Y; Kiflie A
    Sci Rep; 2024 Feb; 14(1):3297. PubMed ID: 38331983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
    Hui X; Gan X; Li Q; Sun W
    Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
    HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P
    AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
    Karabay O
    AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
    Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
    AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
    Kouamou V; Washaya T; Ndhlovu CE; Manasa J
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
    Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
    AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
    Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
    AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.
    Mushy SE; Mtisi E; Mkawe S; Mboggo E; Ndega J; Yahya-Malima KI; Kamugunya D; Kilimba ES; Mlay BS; Muya A; Ngalesoni F
    AIDS Res Ther; 2024 May; 21(1):35. PubMed ID: 38778318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T; Dunga S; Makonokaya L; Woelk G; Maida A; Wang A; Ahimbisibwe A; Chamanga RK; Zimba SB; Kayira D; Machekano R
    BMC Public Health; 2024 May; 24(1):1321. PubMed ID: 38755632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
    Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.
    Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A
    BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.